Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.4K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

403
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
403
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

287
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
287
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

230
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond clinical toxicology: protecting our poisoned patients.

Journal of the Royal Society of Medicine·2026
Same author

Rethinking Statin Dosage in Coronary Disease.

Pharmacology research & perspectives·2025
Same author

The problem of propranolol poisoning.

British journal of clinical pharmacology·2025
Same author

Influence of Blood Pressure Reduction on Pulse Wave Velocity in Primary Hypertension: A Meta-Analysis and Comparison With an Acute Modulation of Transmural Pressure.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational Therapeutics.

Drug safety·2024
Same author

Effectiveness of biosimilar adoption within a UK tertiary hospital: 6-year follow-up.

British journal of clinical pharmacology·2023

Related Experiment Video

Updated: Jan 25, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Antithrombotic dose: Some observations from published clinical trials.

Simon B Dimmitt1,2, Christopher N Floyd3,4, Robin E Ferner5,6

  • 1Division of Internal Medicine, Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Australia.

British Journal of Clinical Pharmacology
|May 4, 2019
PubMed
Summary

Optimizing antithrombotic drug doses is crucial for balancing efficacy and safety. Lower doses of antiplatelet and anticoagulant medications demonstrate significant efficacy with improved safety profiles.

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Jan 25, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Drug Development

Background:

  • Clinical antithrombotic doses require a balance between therapeutic efficacy and patient safety.
  • The derivation of current clinical doses from preclinical and clinical data is not well-documented in existing literature.
  • Limited large randomized controlled trials (RCTs) exist that compare varying antithrombotic doses against placebo.

Purpose of the Study:

  • To investigate the evidence base for current clinical dosing of antithrombotic agents.
  • To evaluate the dose-response relationship for antithrombotic efficacy and safety.
  • To assess whether lower antithrombotic doses could maintain efficacy while improving safety.

Main Methods:

  • Review of published literature, focusing on randomized controlled trials (RCTs) of antithrombotic agents.
  • Analysis of dose selection strategies in RCTs for newer antithrombotics, particularly in relation to noninferiority trials.
  • Examination of data from RCTs regarding the efficacy and safety of aspirin and direct oral anticoagulants at reduced doses.

Main Results:

  • RCT doses for newer antithrombotics may be selected to maximize the likelihood of demonstrating noninferiority against established agents.
  • Aspirin demonstrates antithrombotic efficacy at daily doses below 75 mg.
  • Direct oral anticoagulants show stroke risk reduction in coronary disease patients at doses significantly lower (1/4) than those recommended for atrial fibrillation.

Conclusions:

  • Lower antithrombotic doses, compared to current recommendations, appear to be safer.
  • Substantial antithrombotic efficacy can be maintained with these lower doses.
  • Further research into optimized dosing strategies for antithrombotic agents is warranted to improve patient outcomes.